for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Novavax COVID-19 vaccine shows 90.4% efficacy in late stage trial

June 14 (Reuters) - Novavax Inc said on Monday its COVID-19 vaccine candidate showed 90.4% overall efficacy against the disease in a late-stage trial. (Reporting by Mrinalika Roy in Bengaluru; Editing by Anil D’Silva)

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up